StreetAlpha.app
Home › Stocks › CING

Cingulate Inc. (CING)

Healthcare
Members
LATEST PRICE

Cingulate develops once-a-day ADHD and anxiety medicines using its proprietary drug delivery platform. CING reports earnings on Thu, Nov 12, 2026.

Prices, price targets and earnings estimates for CING are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is CING in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 12
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CING in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for CINGThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
Roth CapitalReiterated
Aug 24Buy
Ascendiant CapitalTarget lowered
Aug 20Buy
Ascendiant CapitalMaintained
Jun 8Buy
HC Wainwright & Co.Reiterated
May 26Buy
DateFirmActionRatingPrice target
Aug 24Roth CapitalReiteratedBuy
Aug 20Ascendiant CapitalTarget loweredBuy
Jun 8Ascendiant CapitalMaintainedBuy
May 26HC Wainwright & Co.ReiteratedBuy
Loading…

Seasonality

How CING has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CING in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CING is in one of them and how their past CING trades turned out.

See how it works→ View all auto pilots→
CING in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CING in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Cingulate

Cingulate is a biopharmaceutical company based in Kansas City, Kansas. It uses its proprietary Precision Timed Release drug delivery platform to develop medicines that release doses at set times, so patients can take them one time a day. Its lead candidate, CTx-1301, is a stimulant for attention deficit hyperactivity disorder and is under review by the U.S. Food and Drug Administration. The company is also developing a buspirone tablet for anxiety, with patients, physicians and payers as its intended users.

Headquarters
Kansas City, KS
Summary based on the company’s 2026 annual report (10-K) ↗